• Search

Meet the Team

Axol Management Team

Jonathan Milner, PhD

Jonathan Milner, PhD

Chairman

Jonathan is an experienced entrepreneur and business leader with a background in genetic research. When he was doing his postdoctoral research at the University of Cambridge, he identified the market opportunity for supplying quality, data-rich antibody products to research communities. In 1998, Jonathan co-founded Abcam, and since then he has led the company from a start-up to become the global leader in the supply of protein research tools.


Liam Taylor

Liam Taylor

CEO

Liam has over 11 years’ C-level experience in both US listed and UK private equity environments, with an emphasis on the diagnostics, pharma and life science sectors, partnering with blue chip global organisations and start-ups alike. A true business leader, Liam spent 10 years with the BBI Group: initially as the Group CFO, before taking on the leadership of BBI Solutions as Managing Director in 2014. BBI Solutions is a leading expert in immunoassay development, biological reagents and manufacturing services. The business revenues more than doubled during his tenure, growing from £23m to over £52m, driven by solid organic growth and strategic acquisitions that built out product and service offerings to its global customer base. After leaving BBI Solutions, Liam worked as a consultant to start-ups in the diagnostics and biotech space, joining Axol Bioscience in July 2020.

Liam is a highly experienced CEO and Managing Director, with extensive knowledge of running commercial, operations, finance and innovations teams. His leadership approach is strongly influenced by his Australian heritage: based on openness, honesty and transparency. He thrives on leading businesses, as well as developing high performing teams and business cultures. Although not a scientist, he is passionate about science with a naturally inquisitive mind and personally aspires to improve end patient outcomes around the world.



Wayne Humphreys 

Chief Financial Officer

A professional Commercial Chief Financial Officer / Finance Director with over 30 years post qualification experience working in fast pace demanding business environments in manufacturing, engineering, sporting, service, and logistics sectors within the UK and overseas, with private equity/venture capital investors.

Strong on business analysis /improvements, cash and working capital management, cost reduction, strategic planning, budgeting, forecasting, management reporting, turnaround, change management, and acquisitions / disposals, delivering commercial “Value for Money” solutions.


Alastair Fleming  

Chief Operations Officer

Alastair joined Axol in Oct 2020 as Chief Operating Officer reuniting with Liam Taylor (CEO) who he had reported to, initially in his 4-year career stint at BBI Solutions Ltd.

He has held senior executive positions in industry, over a career spanning 37 years, within several different sectors, including Pharmaceutical, Medical Device (both as a sub-contractor and equipment manufacturing) and Food. He has a broad business knowledge base having been responsible for the sales, purchasing, quality, business development, human resources, design, health & safety, operations, and finance functions in companies both in Europe and the USA. He is experienced working in both Private Equity and Venture Capital funding models.


Ashley Barnes 

Chief Science Officer

Ashley has latterly spent the last 4 Years at Censo Biotechnologies where as the Chief Scientific Officer he lead the strategy and scientific development of new and novel induced pluripotent stem cells. Coupled to this was the development of robust disease relevant assays including co-culture models for neuroscience and inflammation. for contract research for both Biotech and Pharma. Ashley has extensive experience in the pharma industry having been at GlaxoSmithKline for 25 years in leading teams in Neuroscience, Respiratory and Immunology disease areas for numerous drug discovery programme with technical competencies including molecular biology, gene editing, pharmacology, cell scale -up functional assay development .


Ross Wheatcroft 

Head of Global Sales 

Ross’ focus is to drive the Axol strategy and work with key strategic customers to deliver key iPSC projects and products to help them achieve their critical research faster. Experienced in delivering results and key collaborations, he and his team will work to grow sales for quality human cell culture systems and custom services for disease modelling and drug discovery.

Ross has spent 20 years within Diagnostics and Life Sciences both technically and commercially. He spent 8 years as a Clinical Pathologist developing and validating assays in CRO’s for preclinical toxicology and clinical trials before moving into Commercial Sales. For the last 12 years during his commercial career he has worked across a number of diagnostic and life science companies delivering technologies and assays to new markets, delivering growth and key partnerships.

 


IMG_9589 (2).jpg

Kimberly LaPointe 

Head of Global Product Management

Kimberly leads the product management and marketing strategy primarily responsible for positioning Axol Bioscience as a leading iPSC based technology partner, through new product development strategy, voice of customer input, and tactical channel marketing.  

Prior to joining Axol, Kimberly spent 17 years in various marketing and product management roles related to custom antibody development for both the IVD and Pharmaceutical industries.  Kimberly excels at leveraging her scientific background and marketing expertise to drive messaging and communication of value proposition for life science audiences.  



Sonya Ansell 

Head of Human Resources

Sonya joined Axol in February 2021 as Head of Human Resources.

She has over 15 years generalist HR experience, 10 of which have been at a senior level, predominantly within the Pharmaceutical, Biotech sectors. She has a broad spectrum of experience within HR including employee relations, benefits, recruitment, policies, harmonization and integration of HR following acquisitions and mergers and the implementation of HR Systems (HRIS).